What's new and exciting in ATTR cardiac amyloidosis in 2024

Thank you

The live event has ended. We will be posting a copy of this webinar event on our webpage at www.amyloidosis.org by May 2, 2024. We thank you for attending.

Description

Join Dr. Fredrick Ruberg and Dr. Omar Siddiqi as they discuss the general overview of ATTR treatment with new developments over the past year (APOLLO-B, ATTRibute-CM), currently enrolled trials (HELIOS-B, CARDIO-TTRansform), and future trials (DepleTTR-CM, MAGNITUDE). They will also cover current heart failure therapy updates (SGLT2i) and imaging (evuzamitide). Following the presentation, there will be a live Q & A session to answer any questions.

Contributors

Frederick L. Ruberg, MD

Frederick L. Ruberg, MD is the Thomas J. Ryan Professor of Cardiovascular Medicine and Professor of Radiology at Boston University (BU) Chobanian & Avedisian School of Medicine and Chief, Section of Cardiovascular Medicine at Boston Medical Center (BMC). Dr. Ruberg attended the University of Pennsylvania Perelman School of Medicine, completed internal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, and a fellowship in cardiovascular magnetic resonance imaging at Beth Israel Deaconess Medical Center in Boston. Committed to research mentorship, he directs Workforce Development for the Boston University Clinical and Translational Science Institute (CTSI) and serves as Senior Associate Editor of Circulation: Cardiovascular Imaging. Dr. Ruberg is a Fellow of the American Heart Association and a member of the Association of University Cardiologists. His clinical and research expertise primarily involves cardiac imaging and infiltrative heart disease focused on improving the recognition and care of patients with cardiac amyloidosis, particularly that owing to the hereditary genetic TTR variant Val122Ile (or V122I). He is an investigator on numerous NIH-funded awards including co-PI of the $7.2m NHLBI-funded Screening for Cardiac Amyloidosis with Nuclear Imaging (SCAN-MP, R01 HL139671) study. An active clinical cardiologist at the BU Amyloidosis Center, he has also contributed and co-directed numerous collaborative clinical guidelines initiatives, mostly recently including in 2023 the ACC Expert Consensus Decision Pathway document on The Comprehensive Multidisciplinary Care of Patient with Cardiac Amyloidosis. Dr. Ruberg has been recognized with mentorship (2017) and citizenship (2022) awards from the BU Department of Medicine.
Omar K. Siddiqi, MD

Dr. Omar K. Siddiqi is a non-invasive cardiologist at Boston Medical Center and the Boston University School of Medicine. He is the Program Director of the Cardiovascular Medicine fellowship at Boston University and an educator at the Boston University School of Medicine. Dr. Siddiqi attends in the cardiac amyloidosis clinic at the Boston University Amyloidosis Center. His research interests include the development and supervision of clinical trials, particularly those testing novel cardiac amyloidosis therapies.

Thank you

Description

Contributors

Frederick L. Ruberg, MD

Omar K. Siddiqi, MD